Clinical and radiographic outcomes of pulpotomy materials in permanent teeth: a systematic review of calcium hydroxide, MTA, biodentine, and iRoot BP plus

恒牙牙髓切断术材料的临床和放射学结果:氢氧化钙、MTA、Biodentine 和 iRoot BP plus 的系统评价

阅读:1

Abstract

BACKGROUND: Pulpotomy is increasingly considered a viable treatment for permanent teeth with carious or traumatic pulp exposure, particularly when preserving pulp vitality is desired. Materials such as Calcium Hydroxide (CH), Mineral Trioxide Aggregate (MTA), Biodentine, and iRoot BP Plus have distinct properties. Although many studies report favorable outcomes, direct comparisons between these materials in permanent teeth remain limited, and evidence on their relative long-term performance is inconclusive. This systematic review aimed to evaluate and compare the clinical and radiographic outcomes of CH, MTA, Biodentine, and iRoot BP Plus in permanent teeth, providing evidence to guide material selection in clinical practice. METHODS: A comprehensive search of Cochrane, PubMed, ScienceDirect, Google Scholar, and Sage Journals was conducted for studies published from 2000 up to mid 2025 using keywords such as Pulpotomy, Vital Pulp Treatment (VPT), Calcium Hydroxide (CH), MTA, Biodentine, and iRoot BP Plus. The review followed PRISMA 2020 guidelines and the PICOS framework. The quality of randomized controlled trials was assessed using the Cochrane Risk of Bias 2 (RoB 2) tool, while cohort and case reports were evaluated using the JBI checklist. RESULTS: A total of 1,543 studies were initially identified, and 22 met the inclusion criteria, with follow-up periods ranging from 6 to 45.6 months. Risk of bias assessments indicated sufficient quality for data extraction. MTA demonstrated consistently high success rates (80%-100%), with several studies reporting complete clinical and radiographic success. iRoot BP Plus also showed excellent outcomes (84.6%-100%), with near perfect results in multiple studies. Biodentine achieved success rates from 70.7% to 100%, with most studies above 90%. CH showed more variable performance (37.5%-99.8%), though some trials reported outcomes comparable to MTA. CONCLUSION: MTA and iRoot BP Plus demonstrated superior clinical and radiographic success, with Biodentine as a strong alternative. Although CH showed lower success rates, its long history of use supports its continued relevance. These findings should be interpreted cautiously due to study heterogeneity, the limited number of high-quality trials, and short follow-up in some cases. Further well-designed randomized controlled trials with long-term follow-up are needed to confirm these results and guide material selection for pulpotomy in permanent teeth.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。